Brief: Abbisko Cayman Says Unit Obtained Clinical Trial Approval For Absk121
22/02/2023 01:21
Feb 22 (Reuters) - Abbisko Cayman 2256.HK :
* UNIT HAS OBTAINED CLINICAL TRIAL APPROVAL FROM NATIONAL
MEDICAL
PRODUCTS ADMINISTRATION FOR ABSK121
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration